Bone mineral density in prepubertal asthmatics receiving corticosteroid treatment

J Paediatr Child Health. 2001 Feb;37(1):67-71. doi: 10.1046/j.1440-1754.2001.00628.x.

Abstract

Objective: To examine whether bone mass is reduced in prepubertal, asthmatics receiving high doses of inhaled corticosteroids.

Methodology: A cross-sectional comparison of lumbar spine-bone mineral density (LS-BMD) was undertaken in 76 subjects after stratifying them according to dosage and administration route of corticosteroid.

Results: Weight was the only independent predictor of LS-BMD (r(2) = 0.38). Children receiving greater than 800 microg/day of inhaled corticosteroid plus intermittent oral corticosteroid had a significantly lower weight-adjusted LS-BMD than children treated with 400-800 microg/day of inhaled corticosteroid (mean difference: 0.06 g/cm(2), 95% confidence interval (CI): - 0.02 to - 0.10). A significant difference in weight-adjusted LS-BMD persisted when all children receiving greater than 800 microg/day of inhaled corticosteroid, irrespective of additional oral corticosteroid treatment, were compared with children receiving 400-800 microg/day of inhaled corticosteroid (mean difference: - 0.05 g/cm(2), 95%CI interval: -0.02 to - 0.09). Bone mass was similar in children not receiving any inhaled corticosteroid and those treated with 400-800 microg/day of inhaled corticosteroid.

Conclusions: A reduced bone mass in prepubertal asthmatic children receiving high doses of inhaled corticosteroids may predetermine a compromised peak bone mass and increase osteoporotic fracture risk in adulthood.

MeSH terms

  • Absorptiometry, Photon
  • Administration, Inhalation
  • Administration, Oral
  • Age Factors
  • Analysis of Variance
  • Asthma / drug therapy*
  • Bone Density / drug effects*
  • Child
  • Child, Preschool
  • Cross-Sectional Studies
  • Dose-Response Relationship, Drug
  • Female
  • Glucocorticoids / pharmacology*
  • Glucocorticoids / therapeutic use
  • Humans
  • Linear Models
  • Lumbar Vertebrae / drug effects*
  • Male
  • Prednisolone / pharmacology
  • Prednisolone / therapeutic use

Substances

  • Glucocorticoids
  • Prednisolone